araag2/HINT huggingface dataset:
Clinical trial NCT02667938 (phase 3, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: hcp1303 capsule 5/0.2mg, hcp1303 capsule 5/0.4mg, hgp1201, hcp1303 capsule 5/0.2mg placebo, hcp1303 capsule 5/0.4mg placebo, hgp1201 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  At Visit 1

               1. ≥50 age

               2. BPH(Benign Prostatic Hyperplasia) + Total IPSS(International Prostate Symptom
                  Score) ≥ 13

               3. Abnormal Erectile function ≥ at least 3months based on screening date

          -  At Visit 2 1. Total IPSS ≥ 13

        Exclusion Criteria:

          1. History of hypersensitivity to Tamsulosin or Tadalafil

          2. History of allergy for Sulfonamide

          3. PSA (Prostate Specific Antigen) ≥4ng/mL
Clinical trial NCT02670915 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: faster-acting insulin aspart, insulin aspart, insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria: - Male or female, 1 year above or equal to age below 18 years at the
        time of signing informed consent and below 18 years at the time of randomisation -
        Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by
        laboratory analysis as per local guidelines) - Ongoing daily treatment with a basal-bolus
        insulin regimen using basal insulin analogue or Neutral Protamine Hagedorn (NPH) insulin
        for at least 90 days prior to the screening visit - HbA1c (glycosylated haemoglobin) below
        or equal 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit
        Exclusion Criteria: - More than one episode of diabetic ketoacidosis requiring
        hospitalisation within the last 90 days prior to the screening visit - Treatment with any
        medication for the indication of diabetes or obesity other than stated in the inclusion
        criteria in a period of 90 days before screening
Clinical trial NCT02671500 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV RNA ≥ 10^4 IU/mL at screening

          -  Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy

          -  Any HCV genotype (1, 2, 3, 4, 5, 6 or indeterminate)

          -  HCV treatment-naive or treatment-experienced

          -  Liver imaging within 6 months of Day 1 is required in cirrhotic patients only to
             exclude hepatocellular carcinoma (HCC)

        Key Exclusion Criteria:

          -  Current or prior history of clinically-significant illness (other than HCV),
             gastrointestinal disorder, clinical hepatic decompensation, or post-operative
             condition that could interfere with the absorption of the study drug

          -  Pregnant or nursing female or male with pregnant female partner

          -  Chronic liver disease of a non HCV etiology

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02672592 (phase 3, status: completed)
Conditions: hypogonadism, metabolic syndrome x, obesity
ICD codes: E88.81, G93.41, E88.9, P19.9, E88.89, O21.1, P19.2, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: anakinra, sodium chloride 0.9%
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          1. Informed consent as documented by signature,

          2. Men at the age between 18 and 75 years,

          3. BMI >30 kg/m2 and at least 1 manifestation of the metabolic syndrome (i.e.
             prediabetes, diabetes, hypertension, dyslipidemia),

          4. Total testosterone level <12 nmol/l.

        Exclusion Criteria:

          1. Previous or current medication with testosterone,

          2. Testosterone deficiency of other cause, i.e. primary hypogonadism caused e.g. by
             Klinefelters syndrome, cryptorchidism, condition following orchiectomy. Known
             secondary hypogonadism caused by pituitary adenoma. Patients on antiandrogen
             medication,

          3. Clinical signs of infection in the week before inclusion or history of a severe
             infection during the last 2 months,

          4. Severe immunosuppression (e.g. patients with previously known infection with human
             immunodeficiency virus and a cluster of differentiation 4 (CD4) count below 350 x
             109/L, patients on immunosuppressive therapy after solid organ transplantation and
             neutropenic patients with neutrophil count < 500 x 109/L and patients under
             chemotherapy with neutrophils 500-1000 x 109/L with an expected decrease to values <
             500 x 109/L),

          5. Hematologic disease (leukocyte count < 1.5 x 109/l, hemoglobin < 11 g/dl, platelets
             <100 x 103/µl),

          6. Other clinically significant concomitant disease states (e.g., renal failure
             [Creatinine-Clearance < 30 ml/min], hepatic dysfunction [transaminases >3x upper
             normal range], active carcinoma,

          7. History of tuberculosis,

          8. Known or suspected non-compliance, drug or alcohol abuse,

          9. Contraindications to the class of drugs under study, e.g. known hypersensitivity or
             allergy to anakinra/Kineret®,

         10. Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant,

         11. Previous enrolment into the current study.
Clinical trial NCT02674854 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: pg324 ophthalmic solution 0.02%/0.005%, netarsudil (ar-13324) ophthalmic solution 0.02%, latanoprost ophthalmic solution 0.005%
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. 18 years of age or older (19 years of age or older in Canada)

          2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension(OHT) in both eyes

          3. Unmedicated intraocular pressure >20mmHg and <36mmHg in both eyes at 2 qualification
             visits

          4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

        Ophthalmic:

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             or narrow angles

          3. Unmedicated intraocular pressure ≥36mmHg in either eye or use of more than 2 ocular
             hypotensive medications within 30 days of screening

          4. Known hypersensitivity to any component of the formulation or latanoprost

          5. Previous glaucoma surgery or refractive surgery

          6. Ocular trauma within 6 months prior to screening

          7. Any ocular surgery or non-refractive laser treatment within 3 months prior to
             screening

          8. Recent or current ocular infection or inflammation in either eye

          9. Use of ocular medication in either eye of any kind within 30 days of screening and
             throughout of the study

         10. Mean central corneal thickness >620µm at screening in either eye

         11. Any abnormality preventing reliable applanation tonometry of either eye

             Systemic:

         12. Clinically significant abnormalities in lab tests at screening

         13. Clinically significant systemic disease

         14. Participation in any investigational study within 60 days prior to screening

         15. Systemic medication that could have had a substantial effect on IOP within 30 days
             prior to screening, or anticipated to be used during the study

         16. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control
Clinical trial NCT02675426 (phase 3, status: active, not recruiting)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, upadacitinib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male or female, at least 18 years old.

          -  Diagnosis of Rheumatoid Arthritis (RA) for greater than or equal to 3 months.

          -  Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for
             greater than or equal to 3 months and on a stable dose for greater than or equal to 4
             weeks prior to the first dose of study drug. The following csDMARDs are allowed:
             Methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.

          -  Meets the following minimum disease activity criteria: greater than or equal to 6
             swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled
             (up to 20% of study population) if they have documented evidence of intolerance to
             bDMARDs or limited exposure (less than 3 months) and have satisfied required washout
             periods.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  History of inflammatory joint disease other than RA. History of secondary Sjogren's
             Syndrome is permitted.

          -  Subjects who are considered inadequate responders to bDMARD therapy as determined by
             the Investigator.
Clinical trial NCT02682927 (phase 3, status: active, not recruiting)
Conditions: dravet syndrome, seizure disorder
ICD codes: G40.833, G40.834
Drugs: zx008 (fenfluramine hydrochloride), matching placebo
SMILES: CCNC(C)CC1=CC(=CC=C1)C(F)(F)F, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day
             of the Screening Visit.

          -  Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely
             controlled by current antiepileptic drugs.

          -  Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior
             to screening

          -  All medications or interventions for epilepsy must be stable for at least 4 weeks
             prior to screening and expected to remain stable throughout the study.

          -  No cardiovascular or cardiopulmonary abnormality based on ECHO, ECG or physical
             examination

          -  Parent/caregiver is willing and able to be compliant with diary completion, visit
             schedule and study drug accountability.

        Key Exclusion Criteria:

          -  Pulmonary arterial hypertension.

          -  Current or past history of cardiovascular or cerebrovascular disease, such as cardiac
             valvulopathy, myocardial infarction or stroke.

          -  Current or past history of glaucoma.

          -  Moderate or severe hepatic impairment.

          -  Receiving concomitant therapy with: anorectic agents; monoamine-oxidase inhibitors;
             medications that act via serotonin including serotonin reuptake inhibitors;
             atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine.

          -  Currently receiving or has received stiripentol in the past 21 days prior to
             Screening.

          -  Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or
             phenytoin, or has taken any of these within the past 30 days.

          -  Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD) test at the
             Screening Visit.

          -  A clinically significant medical condition,that would interfere with study
             participation, collection of study data, or pose a risk to the subject.
Clinical trial NCT02684370 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: risankizumab, placebo for risankizumab, ustekinumab, placebo for ustekinumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Male or female patients with age ≥18 years at screening.

          -  Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for
             at least 6 months before the first administration of study drug.

          -  Have stable moderate to severe chronic plaque psoriasis with or without psoriatic
             arthritis at both Screening and Baseline (Randomisation):

               1. Have an involved body surface area (BSA) ≥10% and

               2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and

               3. Have a static Physician Global Assessment (sPGA) score of ≥3.

          -  Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as
             assessed by the investigator.

          -  Must be a candidate for treatment with Stelara® (ustekinumab) according to local
             label.

        Exclusion criteria:

          -  Patients with:

               1. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)

               2. current drug-induced psoriasis (including an exacerbation of psoriasis from beta
                  blockers, calcium channel blockers, or lithium)

               3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis
                  that might confound trial evaluations according to investigator's judgment

          -  Previous exposure to BI 655066.

          -  Previous exposure to ustekinumab (Stelara®).
Clinical trial NCT02686138 (phase 3, status: completed)
Conditions: constipation predominant irritable bowel syndrome
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: tenapanor, placebo
SMILES: CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females aged 18 to 75 years, inclusive

          -  Females must be of non-childbearing potential; If of child-bearing potential, must
             have negative pregnancy test and confirm the use of one of the appropriate means of
             contraception

          -  Males must agree to use appropriate methods of barrier contraception or have
             documented surgical sterilization

          -  Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS

          -  A colonoscopy based on AGA guidelines; every 10 years at ≥50 years old

        Exclusion Criteria:

          -  Functional diarrhea as defined by Rome III criteria

          -  IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III
             criteria

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the GI tract within 6 months prior to screening, or active disease
             within 6 months prior to screening; including but not limited to cancer, inflammatory
             bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer,
             pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus,
             non-controlled GERD, gastrointestinal obstruction or carcinoid syndrome.

          -  Potential CNS cause of constipation (e.g., Parkinson's disease, spinal cord injury, or
             multiple sclerosis)

          -  Subject has a history or current evidence of laxative abuse (in the clinical judgment
             of physician)

          -  Hepatic dysfunction (ALT [SGPT] or AST [SGOT] >2.5 times the upper limit of normal) or
             renal impairment (serum creatinine >2 mg/dL)

          -  Any evidence of or treatment of malignancy (other than localized basal cell, squamous
             cell skin cancer or cancer in situ that has been resected) within the previous year

          -  Any surgery on the stomach, small intestine or colon, excluding appendectomy and
             cholecystectomy (unless within 60 days of screening visit)
Clinical trial NCT02688556 (phase 3, status: completed)
Conditions: keratoconjunctivitis sicca
ICD codes: H16.223, H16.221, H16.222, H16.229
Drugs: cyclosporine, vehicle of otx-101
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  History of dry eye syndrome (KCS) for a period of at least 6 months

          -  Clinical diagnosis of bilateral KCS

          -  Lissamine green conjunctival staining sum score of ≥ 3 to ≤ 9 out of a total possible
             score of 12 (scoring excludes superior zones 2 and 4) in the same eye at both the
             Screening and Baseline Visits.

          -  Global symptom score (SANDE) ≥ 40 mm at both the Screening and Baseline Visits

          -  Corrected Snellen visual acuity (VA) of better than 20/200 in each eye.

        Exclusion Criteria:

          -  Use of cyclosporine ophthalmic emulsion 0.05% (Restasis®) within 3 months prior to the
             Screening Visit.

          -  Previous treatment failure (lack of efficacy) with cyclosporine ophthalmic emulsion
             0.05% (Restasis).

          -  Diagnosis of Sjögren's disease ˃ 5 years prior to the Screening Visit.

          -  Clinical diagnosis or any history of seasonal and/or perennial allergic
             conjunctivitis.

          -  Use of systemic or topical medications within 7 days prior to the Screening Visit or
             during the study period that are known to cause dry eye.

          -  Use of any topical ophthalmic medications, prescription (including anti-glaucoma
             medications) or over the counter (including artificial tears), other than the assigned
             study medication during the study period.

          -  Current active eye disease other than dry wyw syndrome (i.e., any disease for which
             topical or systemic ophthalmic medication is necessary).

          -  History of herpes keratitis.

          -  Corneal transplant

          -  Corneal refractive surgery within 6 months prior to the Screening Visit or
             postoperative refractive surgery symptoms of dryness that have not resolved.

          -  Cataract surgery within 3 months prior to the Screening Visit.
Clinical trial NCT02689180 (phase 3, status: unknown status)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: placebo, furosemide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC(=O)OC[C@H]1O[C@@H](OC2=NN(C(C)C)C(C)=C2CC2=CC=C(OC(C)C)C=C2)[C@H](O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        The ReBIC-1 study will enroll HF outpatients that fulfill the following criteria:

          1. age equal or greater than 18 year-old;

          2. New York Heart Association functional class I or II;

          3. Left Ventricular Ejection Fraction ≤ 45% by transthoracic two-dimensional
             echocardiography performed within 3 months before the screening visit;

          4. no previous HF related hospitalization or visit to emergency room within 6 months
             before the screening visit;

          5. treatment with a stable dose of furosemide (40 or 80 mg per day) for at least 6 months
             before the screening visit;

          6. plasma potassium < 5 mg/dl within 3 months before the screening visit;

          7. optimal HF treatment with an angiotensin converting enzyme inhibitor (ACEi) or
             angiotensin receptor blocker (ARB) and beta-blockers, unless contraindicated or not
             tolerated.

        The ReBIC-1 study will exclude HF outpatients that fulfill the following criteria:

          1. a clinical congestion score (CCS) > 5 points;

          2. prior acute coronary syndrome, stroke or myocardial revascularization within 3 months
             before the screening visit;

          3. any severe valve heart disease (aortic, mitral or tricuspid);

          4. severe pulmonary disease (asthma, emphysema or fibrosis);

          5. severe hepatic failure or cirrhosis;

          6. end-stage acute or chronic renal disease (on hemodialysis);

          7. malignancy on active treatment;

          8. congenital heart disease;

          9. participation on any other interventional clinical research;

         10. inability to understand and sign informed consent.